<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4930207</article-id><article-id pub-id-type="pmid">27367859</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0158579</article-id><article-id pub-id-type="publisher-id">PONE-D-15-48711</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Luminescent Proteins</subject><subj-group><subject>Aequorin</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Physics</subject><subj-group><subject>Electromagnetic Radiation</subject><subj-group><subject>Luminescence</subject><subj-group><subject>Bioluminescence</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>In Vivo Imaging</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Head</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Head</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>DNA construction</subject><subj-group><subject>Plasmid Construction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>DNA construction</subject><subj-group><subject>Plasmid Construction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Material Properties</subject><subj-group><subject>Emission Spectra</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Physics</subject><subj-group><subject>Condensed Matter Physics</subject><subj-group><subject>Solid State Physics</subject><subj-group><subject>Crystallography</subject><subj-group><subject>Crystal Structure</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Hydroxyl Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Hydroxyl Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Hydroxyl Amino Acids</subject><subj-group><subject>Tyrosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="42463" pm="."><plain>Red-Shifted Aequorin Variants Incorporating Non-Canonical Amino Acids: Applications in In Vivo Imaging </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Aequorin in <italic>In Vivo</italic> Imaging</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grinstead</surname><given-names>Kristen M.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ensor</surname><given-names>Charles M.</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Joel</surname><given-names>Smita</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daftarian</surname><given-names>Pirouz</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dikici</surname><given-names>Emre</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zingg</surname><given-names>Jean-Marc</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daunert</surname><given-names>Sylvia</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Biochemistry and Molecular Biology, R. Bunn Gautier Bldg., 1011 NW 15th Street, Miller School of Medicine, University of Miami, Miami, FL, 33136, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Chemistry, 1610 Campus Drive East, Valparaiso University, Valparaiso, IN, 46385, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Jones</surname><given-names>D. Dafydd</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Cardiff University, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="42464" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="42465" pm="."><plain>Conceived and designed the experiments: KG LR PD SD. </plain></SENT>
<SENT sid="42466" pm="."><plain>Performed the experiments: KG PD. </plain></SENT>
<SENT sid="42467" pm="."><plain>Analyzed the data: KG CE ED. </plain></SENT>
<SENT sid="42468" pm="."><plain>Contributed reagents/materials/analysis tools: KG LR CE ED. </plain></SENT>
<SENT sid="42469" pm="."><plain>Wrote the paper: KG LR CE SJ ED PD JZ SD. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>SDaunert@med.miami.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>7</issue><elocation-id>e0158579</elocation-id><history><date date-type="received"><day>6</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Grinstead et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Grinstead et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0158579.pdf"/><abstract><p><SecTag type="ABS"><text><SENT sid="42470" pm="."><plain>The increased importance of in vivo diagnostics has posed new demands for imaging technologies. </plain></SENT>
<SENT sid="42471" pm="."><plain>In that regard, there is a need for imaging molecules capable of expanding the applications of current state-of-the-art imaging in vivo diagnostics. </plain></SENT>
<SENT sid="42472" pm="."><plain>To that end, there is a desire for new reporter molecules capable of providing strong signals, are non-toxic, and can be tailored to diagnose or monitor the progression of a number of diseases. </plain></SENT>
<SENT sid="42473" pm="."><plain>Aequorin is a non-toxic photoprotein that can be used as a sensitive marker for bioluminescence in vivo imaging. </plain></SENT>
<SENT sid="42474" pm="."><plain>The sensitivity of aequorin is due to the fact that bioluminescence is a rare phenomenon in nature and, therefore, it does not suffer from autofluorescence, which contributes to background emission. </plain></SENT>
<SENT sid="42475" pm="."><plain>Emission of bioluminescence in the blue-region of the spectrum by aequorin only occurs when calcium, and its luciferin coelenterazine, are bound to the protein and trigger a biochemical reaction that results in light generation. </plain></SENT>
<SENT sid="42476" pm="."><plain>It is this reaction that endows aequorin with unique characteristics, making it ideally suited for a number of applications in bioanalysis and imaging. </plain></SENT>
<SENT sid="42477" pm="."><plain>Herein we report the site-specific incorporation of non-canonical or non-natural amino acids and several coelenterazine analogues, resulting in a catalog of 72 cysteine-free, aequorin variants which expand the potential applications of these photoproteins by providing several red-shifted mutants better suited to use in vivo. In vivo studies in mouse models using the transparent tissue of the eye confirmed the activity of the aequorin variants incorporating L-4-iodophehylalanine and L-4-methoxyphenylalanine after injection into the eye and topical addition of coelenterazine. </plain></SENT>
<SENT sid="42478" pm="."><plain>The signal also remained localized within the eye. </plain></SENT>
<SENT sid="42479" pm="."><plain>This is the first time that aequorin variants incorporating non-canonical amino acids have shown to be active in vivo and useful as reporters in bioluminescence imaging. </plain></SENT>
</text></SecTag></p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>7R01GM047915</award-id><principal-award-recipient><name><surname>Daunert</surname><given-names>Sylvia</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Lucille P. Markey Chair</institution></funding-source><principal-award-recipient><name><surname>Daunert</surname><given-names>Sylvia</given-names></name></principal-award-recipient></award-group><funding-statement>This study was funded by the National Institutes of Health, grant number 7R01GM047915, and by the Lucille P. Markey Chair. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec001"><title><text><SENT sid="42480" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="42481" pm="."><plain>Imaging is a critical component of medical diagnostics and biomedical research. </plain></SENT>
<SENT sid="42482" pm="."><plain>X-Ray computed tomography, ultrasonography, magnetic resonance imaging (MRI), and positron emission tomography imaging (PET), and optical methods based on fluorescence or bioluminescence are used as stand-alone or in-tandem in diagnostic imaging to provide information on morphological, anatomical, or organ function. </plain></SENT>
<SENT sid="42483" pm="."><plain>Despite their wide use, the majority of these methods do not have the ability to monitor specific molecular events linked to disease states and provide a complete picture of a biochemical process. In vivo imaging systems (IVIS) [1–4] is currently the state-of-the-art instrumentation used in molecular imaging to investigate biological processes in whole animal bioluminescence imaging (BLI) employing reporter technologies. </plain></SENT>
<SENT sid="42484" pm="."><plain>IVIS has a fast image acquisition time (from seconds to a few minutes) and can be used to image several animals at once, providing a high throughput cost-effective alternative. </plain></SENT>
</text></p><p><text><SENT sid="42485" pm="."><plain>“Living light” or bioluminescence, is a naturally occurring phenomenon where light is generated by living organisms. </plain></SENT>
<SENT sid="42486" pm="."><plain>Bioluminescence has several advantages over fluorescence, most notably the high sensitivity shown by the subattomole detection limits in vitro, and low background caused by the lack of inherent bioluminescence in most tissues [5–8]. </plain></SENT>
<SENT sid="42487" pm="."><plain>Furthermore, bioluminescence does not require external illumination, making it suitable for light sensitive organs and tissues such as the retina. </plain></SENT>
</text></p><p><text><SENT sid="42488" pm="."><plain>Bioluminescent studies have frequently been conducted using the intracellular expression of proteins such as firefly luciferase (FLuc) and Renilla luciferase (RLuc) [9–21]. </plain></SENT>
<SENT sid="42489" pm="."><plain>Though these proteins have the benefits of bioluminescence and have been used for in vivo cell tracking and gene expression, they require the incorporation of foreign DNA or the transplant of transgenic tissue [22, 23]. </plain></SENT>
<SENT sid="42490" pm="."><plain>To overcome these drawbacks, we propose the direct administration of engineered red-shifted emission variants of the photoprotein aequorin, a protein employed previously in deep tissue calcium measurements [24]. </plain></SENT>
</text></p><p><text><SENT sid="42491" pm="."><plain>Aequorin is a 22 kDa non-toxic photoprotein originally isolated from the bioluminescent jellyfish Aequorea victoria and employed initially for in vivo calcium detection [25, 26]. </plain></SENT>
<SENT sid="42492" pm="."><plain>In addition, aequorin has found numerous applications in cell trafficking [27, 28], biosensing [29–32], and in bioluminescent competitive [30] and immunoassays [33–41]. </plain></SENT>
<SENT sid="42493" pm="."><plain>Aequorin uses the conversion of the incorporated luciferin coelenterazine to coelenteramide to emit a flash of light at 472 nm. </plain></SENT>
<SENT sid="42494" pm="."><plain>The coelenterazine is bracketed in the hydrophobic pocket by H-bonds with three triads: Tyr184-His169-Trp173, Tyr192-His58-Trp108, and Tyr82-His16-Trp86 [42–44] (Fig 1). </plain></SENT>
<SENT sid="42495" pm="."><plain>The addition of calcium causes a change in the conformation of the protein, triggering the bioluminescence reaction. </plain></SENT>
<SENT sid="42496" pm="."><plain>The availability of different synthetic coelenterazine analogs with a variety of emission maxima and half-lives, allows for the tuning of emitted light [45, 46]. </plain></SENT>
<SENT sid="42497" pm="."><plain>Since wild-type aequorin emits in the blue region of the visible spectrum, and since the emitted light at that particular wavelength is more easily absorbed and scattered by tissue, the availability of red-shifted aequorin mutants is important for further expanding its role in vivo. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0158579.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="42498" pm="."><plain>Structures of wild-type aequorin and the non-natural amino acid analogs employed for site-selective incorporation into the protein. </plain></SENT>
</text></title><p><text><SENT sid="42499" pm="."><plain>(A) Crystal structure of aequorin with the location of the Tyr82-His16-Trp86. </plain></SENT>
<SENT sid="42500" pm="."><plain>The substituted tyrosine is at position 82 and the substituted tryptophan is at position 86. </plain></SENT>
<SENT sid="42501" pm="."><plain>(B) Chemical structure of non-natural amino acids: L-4-aminophenylalanine, (C) L-4-bromophenylalanine, (D) L-4-iodophenylalanine, (E) L-4 methoxyphenylalanine (PDB ID: 1EJ3). </plain></SENT>
<SENT sid="42502" pm="."><plain>Reprinted from [47]under a CC BY license, with permission from Open Access Dissertations, original copyright 2015. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0158579.g001"/></fig></SecTag><p><text><SENT sid="42503" pm="."><plain>In addition to synthetic coelenterazine, random and site-directed mutations have been used by us and others to create a variety of aequorin analogs with different wavelengths of emission and half-lives [8, 46, 48–54]. </plain></SENT>
<SENT sid="42504" pm="."><plain>Although aequorin variants with unique spectral characteristics using canonical amino acids have been created, the range of emission properties can be further tailored by strategic incorporation of non-natural amino acids [46, 53]. </plain></SENT>
</text></p><p><text><SENT sid="42505" pm="."><plain>Previous studies have shown that mutations in the protein sequence involving the Tyr82-His16-Trp86 triads using canonical amino acids have a great effect on the spectral characteristics of aequorin while maintaining its bioluminescent activity, most notably a red-shift in the emission wavelength. </plain></SENT>
<SENT sid="42506" pm="."><plain>This led to the selection of the tyrosine at position 82 and tryptophan at position 86 for replacement in a cysteine-free aequorin variant (hereafter “aequorin“), to minimize the absorption of the signal by tissue during in vivo studies, such as in calcium imaging and in the previously mentioned deep tissue studies [41, 55]. </plain></SENT>
<SENT sid="42507" pm="."><plain>In this study, the tryptophan residue at position 86 was replaced with four different non-natural amino acids L-4-aminophenylalanine (AminoPhe), L-4-bromophenylalanine (BromoPhe), L-4-iodophenylalanine (IodoPhe), and L-4-methoxyphenylalanine (MethoxyPhe). </plain></SENT>
<SENT sid="42508" pm="."><plain>The position was also substituted simultaneously with the tyrosine at position 82. </plain></SENT>
<SENT sid="42509" pm="."><plain>The variants were then complexed with native coelenterazine and eight synthetic coelenterazines cp, f, fcp, h, hcp, i, ip, and n (Fig 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0158579.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="42510" pm="."><plain>Structures of synthetic coelenterazines. </plain></SENT>
</text></title><p><text><SENT sid="42511" pm="."><plain>Reprinted from [47] under a CC BY license, with permission from Open Access Dissertations, original copyright 2015. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0158579.g002"/></fig></SecTag><p><text><SENT sid="42512" pm="."><plain>To test the applicability of these red-shifted aequorin variants for in vivo imaging the variant with the greatest red-shifted wavelength and the variant with the longest half-life were each injected introsomally into the eye of a 6–8 week old ICR (CD1) outbred female mouse. </plain></SENT>
<SENT sid="42513" pm="."><plain>The bioluminescence was then triggered by topical addition of coelenterazine and the emission of light detected with a IVIS instrument. </plain></SENT>
<SENT sid="42514" pm="."><plain>Though aequorin has been part of imaging tissues as difficult to access as the deep brain, [56], the eye was chosen for our initial visualization studies because of its characteristics of optical transparency, simple anatomy, well-defined structure, and easy accessibility. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec id="sec002"><title><text><SENT sid="42515" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><p><text><SENT sid="42516" pm="."><plain>To circumvent the limitations of current luminescent proteins in imaging and expand their use in vivo, we have prepared a catalog of mutants of the tunable photoprotein aequorin [8, 26, 46, 57]. </plain></SENT>
<SENT sid="42517" pm="."><plain>We prepared these variants by site-specifically incorporating non-natural amino acids into selected sites of the hydrophobic pocket of aequorin using Amber Suppression [42, 55, 58, 59]. </plain></SENT>
<SENT sid="42518" pm="."><plain>Previous work in our group employing Amber Suppression replaced a tyrosine residue at position 82 by introducing a TAG codon to create functional non-natural variants of aequorin with red-shifted wavelengths of emission and longer bioluminescence half-lives [46]. </plain></SENT>
<SENT sid="42519" pm="."><plain>In the present study, our group individually incorporated four different non-natural amino acids, specifically, L-4-aminophenylalanine (AminoPhe), L-4-bromophenylalanine (BromoPhe), L-4-iodophenylalanine (IodoPhe), and L-4-methoxyphenylalanine (MethoxyPhe), into aequorin at position 86 alone and 82 and 86 together (Fig 1). </plain></SENT>
<SENT sid="42520" pm="."><plain>These non-natural amino acid residues were selected for their hydrophobicity, aromaticity, and their size similarity to tyrosine and tryptophan [42–44]. </plain></SENT>
<SENT sid="42521" pm="."><plain>By complexing them with native coelenterazine and eight synthetic coelenterazine analogs, this work resulted in 72 new bioluminescent aequorin variants; several of these variants had red-shifted wavelengths of emission, and both shorter and longer bioluminescence half-lives were observed as compared to those of native aequorin. </plain></SENT>
</text></p><p><text><SENT sid="42522" pm="."><plain>Two plasmid systems were developed to express the aequorin variants. </plain></SENT>
<SENT sid="42523" pm="."><plain>The first system incorporated the non-natural amino acids into position 86 using a pBAD/HisA vector by using well-established molecular biology protocols [60] that was co-transformed with pDULE vectors engineered for each non-natural amino acid procured from the Schultz group [61]. </plain></SENT>
<SENT sid="42524" pm="."><plain>This resulted in a system in which the expression of aequorin is tightly regulated by the araBAD promoter and protein expression is induced by the addition of arabinose to the culture medium. </plain></SENT>
<SENT sid="42525" pm="."><plain>The culture was then spun down and aequorin isolated from the supernatant by acid precipitation. </plain></SENT>
<SENT sid="42526" pm="."><plain>Low-level expression of the L-4-aminophenylalanine aequorin prompted the generation of a second system in which the aequorin gene with a TAG codon at position 86 was inserted into a pET30Xa/LIC plasmid. </plain></SENT>
<SENT sid="42527" pm="."><plain>This construct produced a good yield of the 86 variant aequorin and was used in all subsequent experiments (S1 Fig). </plain></SENT>
<SENT sid="42528" pm="."><plain>The pETXa/LIC also included a His6x tag to aid in purification. </plain></SENT>
</text></p><p><text><SENT sid="42529" pm="."><plain>The protein variants were prepared by supplementing the culture media containing the appropriate plasmids with the selected non-natural amino acid and expression was induced with IPTG. </plain></SENT>
<SENT sid="42530" pm="."><plain>The cells were lysed, and the protein variants were isolated and purified using affinity chromatography. </plain></SENT>
<SENT sid="42531" pm="."><plain>Incorporation of the non-natural amino acids was verified by mass spectrometry (S1 Table, S7–S11 Tables) and the resulting variants were complexed with one of nine different coelenterazine analogs: native, cp, f, fcp, h, hcp, i, ip, or n. The resulting aequorin variants were characterized for specific activity, wavelength emission maximum, and bioluminescence emission half-life (S2–S4 Tables). </plain></SENT>
<SENT sid="42533" pm="."><plain>Though not all mutants displayed a marked red-shift and also displayed the loss in specific activity associated with synthetic coelenterazine analogs, several mutant aequorin and synthetic coelenterazine complexes showed suitable emission characteristics. </plain></SENT>
</text></p><p><text><SENT sid="42534" pm="."><plain>The data in Table 1 shows the change in the wavelength maximum emission spectra and bioluminescence emission half-lives for selected variants as well as wild-type aequorin. </plain></SENT>
<SENT sid="42535" pm="."><plain>The aequorin variants with single substitutions at position 86 showed longer bioluminescence emission half-lives than those found in our previous study with an aequorin containing a single non-natural incorporation at position 82. </plain></SENT>
<SENT sid="42536" pm="."><plain>Further, the double non-natural incorporation produces variants with a marked red-shifted wavelength of bioluminescence emission [46]. </plain></SENT>
<SENT sid="42537" pm="."><plain>Most significantly, aequorin with L-4-methoxyphenylalanine at positions 82 and 86 complexed with coelenterazine i emits maximal bioluminescence at 526 nm, which is the largest red-shift of wavelength of any aequorin variant reported thus far and 11 nm longer than the previous most red-shifted aequorin, namely, L-4-methoxyphenylalanine at position 82 [46]. Fig 3 shows the interactions of the tryptophan residue at position 86 with the coelenterazine molecule. </plain></SENT>
<SENT sid="42538" pm="."><plain>By mutating the Trp86, the stability of the phenol ring moiety associated with the Tyr82-His16-Trp86 triad is affected by the change in the H-bond network. </plain></SENT>
<SENT sid="42539" pm="."><plain>In examining the binding interactions of the amino acids in the binding pocket with the newly prepared variant aequorin with L-4-aminophenylalanine and L-4- methoxyphenylalanine, it is evident that these non-natural amino acids, which have an amino group and methoxy group, respectively, are capable of maintaining a polar interaction with coelenterazine, while L-4-bromophenylalanine and L-4-iodophenylanine are not. </plain></SENT>
<SENT sid="42540" pm="."><plain>We postulate that the loss of the H-bonds that stabilize the luciferin could explain the red-shifted emission wavelengths of the halogenated aequorin variants L-4-bromophenylalanine and L-4-iodophenylanine. </plain></SENT>
<SENT sid="42541" pm="."><plain>Also, the presence of iodine in a molecule can increase the transition probability of an electron in an excited singlet state to an excited triplet state, creating a shift in the emission spectra as well as the elongation of the half-life [62]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0158579.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="42542" pm="."><plain>Emission characteristics of selected aequorin variants. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0158579.t001g" xlink:href="pone.0158579.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"><text><SENT sid="42543" pm="."><plain>Aequorin and CTZ </plain></SENT>
</text></th><th align="justify" rowspan="1" colspan="1"><text><SENT sid="42544" pm="."><plain>Wavelength (nm) </plain></SENT>
</text></th><th align="justify" rowspan="1" colspan="1"><text><SENT sid="42545" pm="."><plain>Half-life (s) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42546" pm="."><plain>Wild-type Aequorin and Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42547" pm="."><plain>472 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42548" pm="."><plain>0.5 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42549" pm="."><plain>IodoPhe 86 Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42550" pm="."><plain>499 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42551" pm="."><plain>14.3 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42552" pm="."><plain>IodoPhe 86 i </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42553" pm="."><plain>508 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42554" pm="."><plain>38.01 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42555" pm="."><plain>AminoPhe 82&amp;86 Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42556" pm="."><plain>496 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42557" pm="."><plain>3.57 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42558" pm="."><plain>AminoPhe 82&amp;86 i </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42559" pm="."><plain>515 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42560" pm="."><plain>58.68 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42561" pm="."><plain>BromoPhe 82&amp;86 Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42562" pm="."><plain>500 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42563" pm="."><plain>3.21 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42564" pm="."><plain>BromoPhe 82&amp;86 i </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42565" pm="."><plain>514 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42566" pm="."><plain>55.62 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42567" pm="."><plain>IodoPhe 82&amp;86 Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42568" pm="."><plain>500 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42569" pm="."><plain>4.19 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42570" pm="."><plain>IodoPhe 82&amp;86 i </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42571" pm="."><plain>508 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42572" pm="."><plain>64.74 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42573" pm="."><plain>MethoxyPhe 82&amp;86 Native </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42574" pm="."><plain>513 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42575" pm="."><plain>3.53 </plain></SENT>
</text></td></tr><tr><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42576" pm="."><plain>MethoxyPhe 82&amp;86 i </plain></SENT>
</text></td><td align="justify" rowspan="1" colspan="1"><text><SENT sid="42577" pm="."><plain>526 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="42578" pm="."><plain>48.73 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><SecTag type="FIG"><fig id="pone.0158579.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="42579" pm="."><plain>Native coelenterazine in the binding pocket of aequorin. </plain></SENT>
</text></title><p><text><SENT sid="42580" pm="."><plain>The grey dashed lines represent the Van der Waal surface of the ligand. </plain></SENT>
<SENT sid="42581" pm="."><plain>Green dashed lines with an arrowhead represent an H-bond going from donor to recipient. </plain></SENT>
<SENT sid="42582" pm="."><plain>The structure is based on aequorin’s crystal structure [43](PDB ID: 1EJ3). </plain></SENT>
<SENT sid="42583" pm="."><plain>Reprinted from [47] under a CC BY license, with permission from Open Access Dissertations, original copyright 2015. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0158579.g003"/></fig></SecTag><p><text><SENT sid="42584" pm="."><plain>While all novel non-natural amino acid-modified aequorin variants show an increase in the half-lives of the bioluminescence emission, the most notable half-life changes are associated with the variants containing coelenterazine i. These variants display the longest bioluminescence decay half-lives with an average of approximately 1 minute, while the half-life of aequorin with native coelenterazine is approximately a half second (Table 1). </plain></SENT>
<SENT sid="42586" pm="."><plain>Notably, the aequorin variant with a double substitution of L-4-iodophenylalanine at positions 82 and 86 paired with coelenterazine i has the longest bioluminescence half-life emission time reported as well at approximately 60 s, compared to our own previously reported 14 s with a single L-4-methoxyphenylalanine at position 82 paired with coelenterazine i (Fig 4) [46]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0158579.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="42587" pm="."><plain>Emission wavelengths and bioluminescence half-lives of selected aequorin variants. </plain></SENT>
</text></title><p><text><SENT sid="42588" pm="."><plain>(A) Bioluminescence emission spectra of aequorin with L-4-aminophenylalanine at position 86 with coelenterazine cp (red), aequorin with native coelenterazine (black), and L-4-methoxyphenylalanine at position 82 and 86 with coelenterazine i (green), illustrating the range of emission wavelengths in this study. </plain></SENT>
<SENT sid="42589" pm="."><plain>(B) Half-life bioluminescence decay of aequorin with native coelenterazine (black), L-4-methoxyphenylalanine with coelenterazine n (orange), and L-4-iodophenylalanine with coelenterazine i (blue), illustrating the range of emission half-lives in this study. </plain></SENT>
<SENT sid="42590" pm="."><plain>Reprinted from [47] under a CC BY license, with permission from Open Access Dissertations, original copyright 2015. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0158579.g004"/></fig></SecTag><p><text><SENT sid="42591" pm="."><plain>The increased probability of the transition of the excited electron from singlet state to triplet state due to the heavy atom can explain the differences in half-lives of the coelenterazines that have iodine compared to the ones that do not possess a heavy atom [62]. </plain></SENT>
<SENT sid="42592" pm="."><plain>This trend is also present in the modified aequorins with a L-4-bromophenylalanine substitution, though to a lesser extent. </plain></SENT>
<SENT sid="42593" pm="."><plain>Interestingly, in our previous work, the single substitution of Tyr82 did not display as great an increase in the half-life of the bioluminescence emission as the single substitution at position Trp86, even with coelenterazine i, but, in contrast, they did exhibit greater red-shift in emission wavelength. </plain></SENT>
<SENT sid="42594" pm="."><plain>The variants with non-natural amino acid substitutions at both positions, Tyr82 and Trp86, show a mixed influence of both substitutions, with longer emission half-lives as well as greater red-shifted emission spectra. </plain></SENT>
<SENT sid="42595" pm="."><plain>These emission characteristics may allow for multiplex detection by spatial and temporal resolution through the differentiation of the emission wavelength and time [51]. </plain></SENT>
</text></p><p><text><SENT sid="42596" pm="."><plain>The feasibility of employing the red-shifted aequorin variants for in vivo imaging was explored by injecting the photoproteins into the right eyes (intrastromal as well as antechamber) of anesthetized mice, chosen for their easy accessibility and simple anatomy as well as for the potential to replace fluorescence in eye studies. </plain></SENT>
<SENT sid="42597" pm="."><plain>The variants with L-4-methoxyphenylalanine at positions 82 and 86 and L-4-iodophenylalanine at positions 82 and 86 were chosen for their red-shifted emission wavelength and long bioluminescence half-life, respectively. </plain></SENT>
<SENT sid="42598" pm="."><plain>The left eyes of the mice were only injected with buffers to serve as internal controls. </plain></SENT>
<SENT sid="42599" pm="."><plain>Additionally, mice without aequorin injected into either eye were imaged. Fig 5 shows the imaging experiments performed by intrastromal injection of identical concentrations of aequorin and L-4-methoxyphenylalanine variants. </plain></SENT>
<SENT sid="42600" pm="."><plain>Native coelenterazine was added to the surface of the eye dropwise to turn “on” the light, that is, trigger the emission of the flash of bioluminescence from the photoproteins, which was immediately recorded by the IVIS. </plain></SENT>
<SENT sid="42601" pm="."><plain>External addition of calcium ions was not necessary since the eye already contains an abundance of calcium ions. Fig 5 also shows bioluminescence emission from the aequorin and the L-4-iodophenylalanine variant injected into the antechamber of the eye. </plain></SENT>
<SENT sid="42602" pm="."><plain>The L-4-iodophenylalanine variant was added at a greater concentration due to the lower specific activity exhibited in the in vitro studies (S2 Table). </plain></SENT>
<SENT sid="42603" pm="."><plain>The mice were observed for up to 1 1/2 hours after the addition of the coelenterazine and still displayed bioluminescence, attributed to the time necessary for the coelenterazine to diffuse to the aequorin. </plain></SENT>
<SENT sid="42604" pm="."><plain>There was also no bioluminescent signal outside of the eye itself, demonstrating that the aequorin did not diffuse to other areas after injection. </plain></SENT>
<SENT sid="42605" pm="."><plain>These results with in vivo imaging suggest that these red-shifted aequorin variants could also be used for imaging studies in other tissues or organs in animals in the future. </plain></SENT>
<SENT sid="42606" pm="."><plain>Bioluminescent resonance energy transfer (BRET) employing aequorin has been demonstrated effective in deep tissue studies, thus suggesting that the aequorin designed, prepared, and employed herein could potentially be translated to applications in deeper tissues [63, 64]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0158579.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0158579.g005</object-id><label>Fig 5</label><caption><title><text><SENT sid="42607" pm="."><plain>Bioluminescence emission of selected aequorin variants in an in vivo mouse model. </plain></SENT>
</text></title><p><text><SENT sid="42608" pm="."><plain>Mice received a 5 μL intrastromal or antechamber injection in the right eye with variant aequorin and the left eye with HEPES Buffer. </plain></SENT>
<SENT sid="42609" pm="."><plain>(A,B) Aequorin injected intrastromally at a concentration of 2.7 x 10−5 M, 30 s exposure. </plain></SENT>
<SENT sid="42610" pm="."><plain>(C) Aequorin with L-4-methoxyphenylalanine at positions 82 and 86. </plain></SENT>
<SENT sid="42611" pm="."><plain>(D) HEPES Buffer only in both eyes. </plain></SENT>
<SENT sid="42612" pm="."><plain>(E) Aequorin injected in the antechamber at a concentration of 3.2 x 10−5 M, 60 s exposure. </plain></SENT>
<SENT sid="42613" pm="."><plain>(F) Aequorin with L-4-iodophenylalanine at positions 82 and 86. </plain></SENT>
<SENT sid="42614" pm="."><plain>Images generated with Matlab R2014b and LivingImage 4.4. </plain></SENT>
<SENT sid="42615" pm="."><plain>Reprinted from [47] under a CC BY license, with permission from Open Access Dissertations, original copyright 2015. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0158579.g005"/></fig></SecTag></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions" id="sec003"><title><text><SENT sid="42616" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="42617" pm="."><plain>In conclusion, our data demonstrate that aequorin variants containing non-natural amino acids in place of the tryptophan residue at position 86 and the tyrosine at position 82 showed red-shifted bioluminescence activity when complexed with native coelenterazine. </plain></SENT>
<SENT sid="42618" pm="."><plain>Moreover, the peak emission wavelengths and half-lives of these variants can further be extended by using coelenterazine analogs. </plain></SENT>
<SENT sid="42619" pm="."><plain>Though not all the mutants showed a significant shift and displayed a drop in specific activity associated with coelenterazine analogs, several had shifts beyond 45 nm and were tested in vivo. </plain></SENT>
<SENT sid="42620" pm="."><plain>The aequorin variant with L-4-methoxyphenylalanine at positions 82 and 86 with complexed coelenterazine i displays a Δ56 nm red-shift in bioluminescence emission wavelength, being 526 nm the greatest red-shift reported thus far for an aequorin variant. </plain></SENT>
<SENT sid="42621" pm="."><plain>Thus, this broadens the realm of applications of aequorin variants as reporter molecules in multiplex applications and in vivo imaging. </plain></SENT>
<SENT sid="42622" pm="."><plain>These red-shifted aequorin variants showed excellent performance in imaging experiments when applied to the eye of a mouse, thus demonstrating their potential use in molecular imaging for diagnostics and/or management of disease. </plain></SENT>
<SENT sid="42623" pm="."><plain>In summary, the red-shifted aequorin variants prepared and reported herein demonstrated improved characteristics for in vivo imaging with regard to our previously reported photoproteins, broadening the applications of aequorin in biomedical analysis and diagnostics. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec004"><title><text><SENT sid="42624" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec005"><title><text><SENT sid="42625" pm="."><plain>Ethics statement </plain></SENT>
</text></title><p><text><SENT sid="42626" pm="."><plain>All animal procedures were performed in compliance with the Association for Research and Vision in Ophthalmology (ARVO) Statement for the use of Animals in Ophthalmic and Vision Research and in accordance with the Guide for the Care and Use of Laboratory Animals (protocol 13–034) published by the National Institutes of Health and approved by the Animal Care and Use Committee of the University of Miami. </plain></SENT>
</text></p></sec><sec id="sec006"><title><text><SENT sid="42627" pm="."><plain>Reagents </plain></SENT>
</text></title><p><text><SENT sid="42628" pm="."><plain>The pBAD/His A and Terrific Broth (TB) are from Invitrogen (Carlsbad, CA). </plain></SENT>
<SENT sid="42629" pm="."><plain>The PET-30 Xa/LIC Kit and Xa Factor Cleavage Capture Kit are from Novagen (Madison, WI). </plain></SENT>
<SENT sid="42630" pm="."><plain>NcoI and HindIII restriction endonucleases are from New England Biolabs (Boston, MA). </plain></SENT>
<SENT sid="42631" pm="."><plain>All natural amino acids, and all antibiotics, are from Sigma-Aldrich (St. Louis, MO). </plain></SENT>
<SENT sid="42632" pm="."><plain>LB agar and LB broth are from Fischer Scientific (Fair Lawn, NJ). </plain></SENT>
<SENT sid="42633" pm="."><plain>The coelenterazines are from Gold Biotechnology (St. Louis, MO). </plain></SENT>
<SENT sid="42634" pm="."><plain>The L-4-aminophenylalanine, L-4-bromophenylalanine, L-4-iodophenylalanine, and L-4-methoxyphenylalanine are from Peptech (Burlington, MA). </plain></SENT>
</text></p></sec><sec id="sec007"><title><text><SENT sid="42635" pm="."><plain>Apparatus </plain></SENT>
</text></title><p><text><SENT sid="42636" pm="."><plain>Cells were grown in a Thermo-Fisher Scientific orbital shaker incubator at 37°C. </plain></SENT>
<SENT sid="42637" pm="."><plain>Cell cultures were harvested using a Beckman J2-MI centrifuge. </plain></SENT>
<SENT sid="42638" pm="."><plain>The proteins were purified using a BioCad Sprint Perfusion Chromatography System (Perseptive Biosystems, Farmington, MA) using 20 mL DEAE Waters AP-2 Anion Exchange Column (Waters Corporation, Milford, MA). </plain></SENT>
<SENT sid="42639" pm="."><plain>The buffers for the purification of the protein were 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA (Buffer A) and 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA, and 1 M NaCl (Buffer B). </plain></SENT>
<SENT sid="42640" pm="."><plain>Diafiltration was performed using a tangential flow separation module with hollow fiber filter membrane (Spectrum Labs, Rancho Dominguez, CA) using 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA. </plain></SENT>
<SENT sid="42641" pm="."><plain>Ni-NTA Agarose beads are from Qiagen (Venlo, Netherlands). </plain></SENT>
<SENT sid="42642" pm="."><plain>Amicon Ultra-15 Centrifugal Filter Units are from EMD (Billerica, MA). </plain></SENT>
<SENT sid="42643" pm="."><plain>Purity of the proteins was confirmed by the appearance of a single band after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a Novex Mini-cell apparatus from Invitrogen and staining with Coomassie Brilliant Blue. </plain></SENT>
<SENT sid="42644" pm="."><plain>Aequorin activity was measured using an Optocomp I luminometer (MGM Biomedical Hamden, CT). </plain></SENT>
<SENT sid="42645" pm="."><plain>The emission spectra of the aequorins were determined using a custom made SpectroScan instrument (ScienceWares, Falmouth, MA), which is capable of obtaining spectra from flash reactions of luminescent samples that emit in the 400–700 nm range. </plain></SENT>
<SENT sid="42646" pm="."><plain>Half-life scans were taken using a Polarstar Optimax 96 well microplate reading luminometer (BMG Labtech, Ortenberg, Germany). </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="42647" pm="."><plain>Construction of the pDULE-pBADHisA-AEQTAG86 expression strains </plain></SENT>
</text></title><p><text><SENT sid="42648" pm="."><plain>Four pDULE vectors which allow for the site-specific incorporation of four different non-natural amino acids were obtained from Dr. Peter Schultz (Scripps Research Institute, La Jolla CA) and Dr. Ryan Mehl (Franklyn and Marshall College, Lancaster, PA) [61]. </plain></SENT>
<SENT sid="42649" pm="."><plain>Each of these pDULE plasmids coded for a tRNACUA and tRNACUA-synthetase specific for the TAG codon and a single non-natural amino acid, either L-4-aminophenylalanine, L-4-bromophenylalanine, L-4-iodophenylalanine, or L-4-methoxyphenylalanine. </plain></SENT>
<SENT sid="42650" pm="."><plain>These plasmids were transformed into Escherichia coli DH10B cells and transformants were selected by plating on LB agar medium containing ampicillin (100 μg/mL) and tetracycline (12 μg/mL). </plain></SENT>
<SENT sid="42651" pm="."><plain>The presence of the pDULE plasmid was confirmed by plasmid isolation, restriction enzyme digestion and DNA gel electrophoresis. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="42652" pm="."><plain>Construction of the pDULE-pET30AEQ8286TAG expression strains </plain></SENT>
</text></title><p><text><SENT sid="42653" pm="."><plain>The four pDULE plasmids were transformed into E. coli DH10B cells with pET30AEQ8286TAG and transformants were selected by plating on LB agar medium containing tetracycline (12 μg/mL) and kanamycin (35 μg/mL). </plain></SENT>
<SENT sid="42654" pm="."><plain>The presence of the pDULE plasmid was confirmed by plasmid isolation, restriction enzyme digestion and DNA gel electrophoresis. </plain></SENT>
</text></p><p><text><SENT sid="42655" pm="."><plain>pBADAEQ86TAG was prepared by inserting the AEQTAG86 gene with the ompA leader sequence attached into pBAD/HisA. </plain></SENT>
<SENT sid="42656" pm="."><plain>The pIN4AEQ86TAG vector containing the cysteine-free aequorin gene fused to the ompA leader sequence was used as a template. </plain></SENT>
<SENT sid="42657" pm="."><plain>The primers were designed so the resulting DNA sequence contained an NcoI site at the 5’ end and a HindIII site at the 3’ end. </plain></SENT>
</text></p><p><text><SENT sid="42658" pm="."><plain>The following primers were used for the cloning of ompA:AEQ86TAG fusion into pBAD/HisA vector (restriction sites for cloning are underlined). </plain></SENT>
</text></p><sec id="sec010"><title><text><SENT sid="42659" pm="."><plain>AEQforpBAD </plain></SENT>
</text></title><p><text><SENT sid="42660" pm="."><plain>5'-CCATGGGTATGAAAAAGACAGCTATCGCGATTGC-3’ </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="42661" pm="."><plain>AEQrevpBAD </plain></SENT>
</text></title><p><text><SENT sid="42662" pm="."><plain>5'AAGCTTAGGGGACAGCTCCACCGTAGAGCTTTTCGGAAGCAGGATCCATTGTGTAC-3’ </plain></SENT>
</text></p><p><text><SENT sid="42663" pm="."><plain>The resulting PCR product was gel purified and cloned into the pCR®II-TOPO® vector by using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). </plain></SENT>
<SENT sid="42664" pm="."><plain>The plasmid from the TA clone was then isolated and sequenced to confirm the presence of the insert. </plain></SENT>
<SENT sid="42665" pm="."><plain>The ompA:AEQ86TAG insert from the TOPO TA clone was then ligated into the NcoI and HindIII sites of pBAD/His A to create pBADHisA-AEQ86TAG. </plain></SENT>
</text></p><p><text><SENT sid="42666" pm="."><plain>The AEQTAG86 gene was also cloned into a pET30 Xa/LIC Vector using primers designed according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="42667" pm="."><plain>pET30AEQ8286TAG was then prepared by using a pair of primers to create a site-specific mutation consisting of a TAG at position 82 (underlined). </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="42668" pm="."><plain>Oligo HPLCTAG8286for </plain></SENT>
</text></title><p><text><SENT sid="42669" pm="."><plain>5'-GGAAACTGATTGGCCTGCATAGATTGAAGG-3’ </plain></SENT>
</text></p></sec><sec id="sec013"><title><text><SENT sid="42670" pm="."><plain>HPLCTAG8286rev </plain></SENT>
</text></title><p><text><SENT sid="42671" pm="."><plain>5'-CCTTCAATCTATGCAGGCCAATCAGTTTCC-3’ </plain></SENT>
</text></p><p><text><SENT sid="42672" pm="."><plain>pBADHisA-AEQ86TAG and pET30AEQ8286TAG vectors were transformed into chemically competent E. coli DH10B cells that already contained the pDULE plasmids to produce four different strains, each specific for the incorporation one of the four non-natural amino acids mentioned above. </plain></SENT>
<SENT sid="42673" pm="."><plain>Selection for transformants was performed by plating on LB agar medium containing both ampicillin (100 μg/mL) kanamycin (35 μg/mL) for cells containing pBADHisA-AEQ86TAG and tetracycline (12 μg/mL) and kanamycin (35 μg/mL) for cells containing pET30AEQ8286TAG. </plain></SENT>
</text></p></sec></sec><sec id="sec014"><title><text><SENT sid="42674" pm="."><plain>Expression and isolation of aequorin variants from pBADHisA-AEQ86TAG </plain></SENT>
</text></title><p><text><SENT sid="42675" pm="."><plain>The cells harboring the pDULE systems with pBADHisA-AEQ86TAG vector were grown in 25 mL of LB broth containing ampicillin (100 μg/mL) and tetracycline (12 μg/mL). </plain></SENT>
<SENT sid="42676" pm="."><plain>All cultures, unless specified otherwise, were grown overnight at 37°C with shaking at 250 rpm. </plain></SENT>
<SENT sid="42677" pm="."><plain>These overnight cultures were used to inoculate 500 mL of LB broth containing the appropriate antibiotics and the cultures were grown at 37°C at 250 rpm to an OD600 between 0.4–0.6. </plain></SENT>
<SENT sid="42678" pm="."><plain>The corresponding non-natural amino acid was then added to a final concentration of 1 mM. </plain></SENT>
<SENT sid="42679" pm="."><plain>The culture was allowed to grow for 1 hour and then induced with arabinose (0.2% final concentration) overnight. </plain></SENT>
</text></p><p><text><SENT sid="42680" pm="."><plain>The culture was centrifuged at 15,300 xg for 20 min and the pellet discarded. </plain></SENT>
<SENT sid="42681" pm="."><plain>The supernatant was acid precipitated using 12 M HCl, then spun again. </plain></SENT>
<SENT sid="42682" pm="."><plain>The pellet was resuspended in Tris-HCl, pH 7.5, containing 2 mM EDTA. </plain></SENT>
</text></p></sec><sec id="sec015"><title><text><SENT sid="42683" pm="."><plain>Expression and isolation of aequorin variants from pET30AEQ8286TAG </plain></SENT>
</text></title><p><text><SENT sid="42684" pm="."><plain>The cells were grown in 25 mL of Terrific broth (TB) containing tetracycline (12 μg /mL) and kanamycin (35 μg/mL) overnight at 37°C at 250 rpm. </plain></SENT>
<SENT sid="42685" pm="."><plain>The overnight cultures were used to inoculate 500 mL of TB broth containing the same antibiotics and the cultures were grown at 37°C at 250 rpm. </plain></SENT>
<SENT sid="42686" pm="."><plain>After growing to an OD600 between 0.4–0.6, the corresponding non-natural amino acid was added to a final concentration of 1 mM. </plain></SENT>
<SENT sid="42687" pm="."><plain>The culture was allowed to grow for 1 hour and then induced with 1 mM IPTG and grown overnight. </plain></SENT>
</text></p><p><text><SENT sid="42688" pm="."><plain>The culture was centrifuged at 15,300 xg for 20 min and the pellet was boiled for 5 min in Native Purification Buffer (50 mM NaH2PO4, 0.5 M NaCl, 1 mM Imidazole, pH = 8.0). </plain></SENT>
<SENT sid="42689" pm="."><plain>The boiled pellet was centrifuged again and the supernatant added to 1 mL of suspended Ni-NTA agarose beads and rotated on a Mini Labroller (Labnet, Woodridge, NJ) at room temperature for 2 hours. </plain></SENT>
<SENT sid="42690" pm="."><plain>The protein was eluted off the column using a PBS Buffer with 20 mM imidazole at pH = 8.0 and digested with Xa factor according to manufacturer’s instructions until all the His tag was cleaved from the protein. </plain></SENT>
<SENT sid="42691" pm="."><plain>The Xa factor was removed with Xa factor Agarose capture beads. </plain></SENT>
<SENT sid="42692" pm="."><plain>The cleaved aequorin was then concentrated using Amicon Ultra spin columns. </plain></SENT>
</text></p></sec><sec id="sec016"><title><text><SENT sid="42693" pm="."><plain>Determination of activities of aequorin variants </plain></SENT>
</text></title><p><text><SENT sid="42694" pm="."><plain>Aequorin was diluted with 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA, to 1x10-7 M and charged with 1x10-4 M coelenterazine overnight. </plain></SENT>
<SENT sid="42695" pm="."><plain>Aequorin activity was triggered by injecting 100 μL of 100 mM Tris-HCl, pH 7.5, containing 100 mM CaCl2. </plain></SENT>
<SENT sid="42696" pm="."><plain>Bioluminescence intensity was measured at 0.1 s intervals for up to 6 s on an Optocomp I luminometer (MGM Biomedical Hamden, CT). </plain></SENT>
<SENT sid="42697" pm="."><plain>Units are in Relative Light Units (RLU) per mole. </plain></SENT>
<SENT sid="42698" pm="."><plain>N = 3 or more, standard deviation is 5% or less. </plain></SENT>
</text></p></sec><sec id="sec017"><title><text><SENT sid="42699" pm="."><plain>Emission spectra of aequorin variants </plain></SENT>
</text></title><p><text><SENT sid="42700" pm="."><plain>A 1 x 10−6 M sample of each aequorin was charged by incubating overnight at 4°C with 1x10-4 M of each of the different coelenterazines and 150 μL of each charged aequorin was pipetted into a 96-well microtiter plate and following injection of 100 μL of 100 mM Tris-HCl, pH 7.5, containing 100 mM CaCl2, the emission spectra was collected for 10 s over a scanning range of 400–700 nm in 1.5 nm increments on a custom made SpectroScan instrument (ScienceWares, Falmouth, MA). </plain></SENT>
<SENT sid="42701" pm="."><plain>N = 3 or more, standard deviation is 5% or less. </plain></SENT>
</text></p></sec><sec id="sec018"><title><text><SENT sid="42702" pm="."><plain>Half-life determination of aequorin variants </plain></SENT>
</text></title><p><text><SENT sid="42703" pm="."><plain>A 1x10-6 M sample of each aequorin variant was charged overnight at 4°C with the 1x10-4 M of the coelenterazine analogue used during the collection of emission spectra. </plain></SENT>
<SENT sid="42704" pm="."><plain>A Polarstar Optimax 96 well microplate luminometer (BMG Labtech, Ortenberg, Germany) was utilized for the half-life measurements. </plain></SENT>
<SENT sid="42705" pm="."><plain>Filters were not required. </plain></SENT>
<SENT sid="42706" pm="."><plain>The bioluminescence signal of a 50 μL sample was collected between 30 s to 150 s, depending on the expected half-life of the aequorin analogue, following the injection of 100 μL of triggering buffer (100 mM Tris-HCl, pH 7.5, containing 100 mM CaCl2). </plain></SENT>
<SENT sid="42707" pm="."><plain>The mean bioluminescence decay spectra was fit with an exponential decay equation using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA), and an equation for first order decay kinetics was used to calculate the bioluminescence half-life of each aequorin-coelenterazine pair. </plain></SENT>
<SENT sid="42708" pm="."><plain>N = 3 or more, standard deviation is 5% or less. </plain></SENT>
</text></p></sec><sec id="sec019"><title><text><SENT sid="42709" pm="."><plain>Mass spectrometry </plain></SENT>
</text></title><p><text><SENT sid="42710" pm="."><plain>Proteins were run on SDS-PAGE and cut out of the stained gels with Coomassie Blue. </plain></SENT>
<SENT sid="42711" pm="."><plain>Gel pieces were digested with trypsin, and an LC-ESI-MS-MS was performed using a ThermoFinnigan LTQ. </plain></SENT>
<SENT sid="42712" pm="."><plain>Resulting MS-MS spectra were compared with proteins in the Swiss-Prot database using the X!Tandem search engine to look for the presence of the substitution of the non-natural amino acid at and only at the target positions. </plain></SENT>
</text></p></sec><sec id="sec020"><title><text><SENT sid="42713" pm="."><plain>In vivo imaging </plain></SENT>
</text></title><p><text><SENT sid="42714" pm="."><plain>The aequorin variants were dissolved in a HEPES Buffer (10 mM HEPES, 0.15 M NaCl at pH = 7.4) at concentrations from 9.1 x 10−6 M to 4.5 x 10−5 M. All mice were anesthetized with a 100 μL ketamine/xylazine (1.5 mg/0.3 mg) by intraperitoneal injection before the injection of the sample. </plain></SENT>
<SENT sid="42716" pm="."><plain>The aequorin samples were injected into one eye of six mice via intrastromal injection in 5 μL volumes, or into the antechamber at a volume of 10 μL, of each of the ICR (CD1) outbred female mice (6–8 weeks old, purchased from Taconic (Germantown, NY)). </plain></SENT>
<SENT sid="42717" pm="."><plain>The same volumes of plain HEPES were injected into the other eye to serve as an internal control. </plain></SENT>
<SENT sid="42718" pm="."><plain>Native coelenterazine was diluted in PBS buffer to a volume of 2.3 x 10−4 M and dropped onto the surface of each eye in 1 μL volumes. </plain></SENT>
<SENT sid="42719" pm="."><plain>The mice were then placed in a Caliper/Xenogen IVIS® SPECTRUM (Caliper, Hopkinton, MA) in the IVIS Small Animal Imaging Facility at the Oncogenmonics Core Facility, Miller School of Medicine, with oxygen flowing into the imaging chamber. </plain></SENT>
<SENT sid="42720" pm="."><plain>Images were taken over 30 s to 60 s. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec021"><title><text><SENT sid="42721" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0158579.s001"><label>S1 Fig</label><caption><title><text><SENT sid="42722" pm="."><plain>Plasmids for expression of aequorin variant proteins. </plain></SENT>
</text></title><p><text><SENT sid="42723" pm="."><plain>(A) pBAD-based plasmid inducible by arabinose for the expression of variant aequorin with a singular amber mutation at position 86. </plain></SENT>
<SENT sid="42724" pm="."><plain>(B) pET30-based plasmid inducible by IPTG for the expression of aequorin with an amber mutation at positions 82 and 86 and the sequence encoding for a His6xtag at the N-terminus. </plain></SENT>
</text></p><p><text><SENT sid="42725" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s001.doc"><caption><p><text><SENT sid="42726" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s002"><label>S2 Fig</label><caption><title><text><SENT sid="42727" pm="."><plain>SDS Gel Showing Purified Aequorin and Aequorin with L-4-iodophenylalanine at position 82 and 86. </plain></SENT>
</text></title><p><text><SENT sid="42728" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s002.doc"><caption><p><text><SENT sid="42729" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s003"><label>S1 Table</label><caption><title><text><SENT sid="42730" pm="."><plain>Mass spectrometry data for the aequorin mutants. </plain></SENT>
</text></title><p><text><SENT sid="42731" pm="."><plain>(A) Mass spectrometry for a single substitution. </plain></SENT>
<SENT sid="42732" pm="."><plain>Tryptophan 86 is located at the end of the peptide fragment (W*). </plain></SENT>
<SENT sid="42733" pm="."><plain>(B) Mass spectrometry data for a double substitution. </plain></SENT>
<SENT sid="42734" pm="."><plain>Tyrosine 82 is located near the middle of the fragment (Y*). </plain></SENT>
</text></p><p><text><SENT sid="42735" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s003.doc"><caption><p><text><SENT sid="42736" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s004"><label>S2 Table</label><caption><title><text><SENT sid="42737" pm="."><plain>Specific activity of aequorin variants: (A) Single substitution at position 86 and (B) Double substitution aequorin variants at positions 82 and 86. </plain></SENT>
</text></title><p><text><SENT sid="42738" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s004.doc"><caption><p><text><SENT sid="42739" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s005"><label>S3 Table</label><caption><title><text><SENT sid="42740" pm="."><plain>Emission wavelengths of aequorin variants. </plain></SENT>
</text></title><p><text><SENT sid="42741" pm="."><plain>(A) Single substitution at position 86 and (B) Double substitutions at 82 and 86 in nm. </plain></SENT>
<SENT sid="42742" pm="."><plain>N = 3 or more, standard deviation is 5% or less. </plain></SENT>
</text></p><p><text><SENT sid="42743" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s005.doc"><caption><p><text><SENT sid="42744" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s006"><label>S4 Table</label><caption><title><text><SENT sid="42745" pm="."><plain>Emission half-lives of aequorin variants. </plain></SENT>
</text></title><p><text><SENT sid="42746" pm="."><plain>(A) Single substitution at position 86 and (B) Double substitutions at 82 and 86. </plain></SENT>
<SENT sid="42747" pm="."><plain>The half-life values of the bioluminescence are in s. N = 3 or more, standard deviation is 5% or less. </plain></SENT>
</text></p><p><text><SENT sid="42749" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s006.doc"><caption><p><text><SENT sid="42750" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s007"><label>S5 Table</label><caption><title><text><SENT sid="42751" pm="."><plain>Mass Spectrometry Data for AminoPhe86AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42752" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s007.doc"><caption><p><text><SENT sid="42753" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s008"><label>S6 Table</label><caption><title><text><SENT sid="42754" pm="."><plain>Mass Spectrometry Data for BromoPhe86AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42755" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s008.doc"><caption><p><text><SENT sid="42756" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s009"><label>S7 Table</label><caption><title><text><SENT sid="42757" pm="."><plain>Mass Spectrometry Data for IodoPhe86AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42758" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s009.doc"><caption><p><text><SENT sid="42759" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s010"><label>S8 Table</label><caption><title><text><SENT sid="42760" pm="."><plain>Mass Spectrometry Data for MethoxyPhe86AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42761" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s010.doc"><caption><p><text><SENT sid="42762" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s011"><label>S9 Table</label><caption><title><text><SENT sid="42763" pm="."><plain>Mass Spectrometry Data for BromoPhe8286AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42764" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s011.doc"><caption><p><text><SENT sid="42765" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s012"><label>S10 Table</label><caption><title><text><SENT sid="42766" pm="."><plain>Mass Spectrometry Data for IodoPhe8286AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42767" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s012.doc"><caption><p><text><SENT sid="42768" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0158579.s013"><label>S11 Table</label><caption><title><text><SENT sid="42769" pm="."><plain>Mass Spectrometry Data for MethoxyPhe8286AEQ. </plain></SENT>
</text></title><p><text><SENT sid="42770" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0158579.s013.doc"><caption><p><text><SENT sid="42771" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="42772" pm="."><plain>S.D. is grateful for the financial support by the Lucille P. Markey Chair from the Miller School of Medicine of the University of Miami. </plain></SENT>
<SENT sid="42774" pm="."><plain>The authors are grateful to Dr. Peter Schultz of the Scripps Research Institute, La Jolla, CA for generously donating the pDULE plasmid. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0158579.ref001"><text><SENT sid="42775" pm="."><plain>1NegrinRS, ContagCH. In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nature reviews Immunology. 2006;6(6):484–90. 10.1038/nri1879 .<?supplied-pmid 16724101?>16724101 </plain></SENT>
</text></ref><ref id="pone.0158579.ref002"><text><SENT sid="42776" pm="."><plain>2ShindeR, PerkinsJ, ContagCH. Luciferin derivatives for enhanced in vitro and in vivo bioluminescence assays. Biochemistry. 2006;45(37):11103–12. 10.1021/bi060475o .<?supplied-pmid 16964971?>16964971 </plain></SENT>
</text></ref><ref id="pone.0158579.ref003"><text><SENT sid="42777" pm="."><plain>3Photoproteins in Bioanalysis. DaunertS, DeoS, editors. Weinheim, DE: Wiley-VCH; 2006 240 p. </plain></SENT>
</text></ref><ref id="pone.0158579.ref004"><text><SENT sid="42778" pm="."><plain>4DeA, GambhirSS. Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2005;19(14):2017–9. 10.1096/fj.05-4628fje .<?supplied-pmid 16204354?>16204354 </plain></SENT>
</text></ref><ref id="pone.0158579.ref005"><text><SENT sid="42779" pm="."><plain>5DothagerRS, FlentieK, MossB, PanMH, KesarwalaA, Piwnica-WormsD. Advances in bioluminescence imaging of live animal models. Current opinion in biotechnology. 2009;20(1):45–53. 10.1016/j.copbio.2009.01.007 <?supplied-pmid 19233638?>19233638 </plain></SENT>
</text></ref><ref id="pone.0158579.ref006"><text><SENT sid="42780" pm="."><plain>6Dragulescu-AndrasiA, ChanCT, DeA, MassoudTF, GambhirSS. Bioluminescence resonance energy transfer (BRET) imaging of protein-protein interactions within deep tissues of living subjects. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(29):12060–5. 10.1073/pnas.1100923108 <?supplied-pmid 21730157?>21730157 </plain></SENT>
</text></ref><ref id="pone.0158579.ref007"><text><SENT sid="42781" pm="."><plain>7PrescherJA, ContagCH. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Current opinion in chemical biology. 2010;14(1):80–9. 10.1016/j.cbpa.2009.11.001 .<?supplied-pmid 19962933?>19962933 </plain></SENT>
</text></ref><ref id="pone.0158579.ref008"><text><SENT sid="42782" pm="."><plain>8RoweL, DikiciE, DaunertS. Engineering Bioluminescent Proteins: Expanding their Analytical Potential. Anal Chem. 2009;81(21):8662–8. 10.1021/Ac9007286. ISI:000276191900007. <?supplied-pmid 19725502?>19725502 </plain></SENT>
</text></ref><ref id="pone.0158579.ref009"><text><SENT sid="42783" pm="."><plain>9CaiW, ChenX. Nanoplatforms for targeted molecular imaging in living subjects. Small. 2007;3(11):1840–54. 10.1002/smll.200700351 .<?supplied-pmid 17943716?>17943716 </plain></SENT>
</text></ref><ref id="pone.0158579.ref010"><text><SENT sid="42784" pm="."><plain>10ChoyG, O'ConnorS, DiehnFE, CostourosN, AlexanderHR, ChoykeP, et al Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. BioTechniques. 2003;35(5):1022–6, 8–30. .<?supplied-pmid 14628676?>14628676 </plain></SENT>
</text></ref><ref id="pone.0158579.ref011"><text><SENT sid="42785" pm="."><plain>11MassoudTF, GambhirSS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes &amp; development. 2003;17(5):545–80. 10.1101/gad.1047403 .<?supplied-pmid 12629038?>12629038 </plain></SENT>
</text></ref><ref id="pone.0158579.ref012"><text><SENT sid="42786" pm="."><plain>12O'NeillK, LyonsSK, GallagherWM, CurranKM, ByrneAT. Bioluminescent imaging: a critical tool in pre-clinical oncology research. The Journal of pathology. 2010;220(3):317–27. 10.1002/path.2656 .<?supplied-pmid 19967724?>19967724 </plain></SENT>
</text></ref><ref id="pone.0158579.ref013"><text><SENT sid="42787" pm="."><plain>13PantaleoMA, NanniniM, MaledduA, FantiS, AmbrosiniV, NanniC, et al Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer treatment reviews. 2008;34(2):103–21. 10.1016/j.ctrv.2007.10.001 .<?supplied-pmid 18055120?>18055120 </plain></SENT>
</text></ref><ref id="pone.0158579.ref014"><text><SENT sid="42788" pm="."><plain>14RazgulinA, MaN, RaoJ. Strategies for in vivo imaging of enzyme activity: an overview and recent advances. Chemical Society reviews. 2011;40(7):4186–216. 10.1039/c1cs15035a .<?supplied-pmid 21552609?>21552609 </plain></SENT>
</text></ref><ref id="pone.0158579.ref015"><text><SENT sid="42789" pm="."><plain>15WeisslederR, PittetMJ. Imaging in the era of molecular oncology. Nature. 2008;452(7187):580–9. 10.1038/nature06917 <?supplied-pmid 18385732?>18385732 </plain></SENT>
</text></ref><ref id="pone.0158579.ref016"><text><SENT sid="42790" pm="."><plain>16BhaumikS, GambhirSS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(1):377–82. 10.1073/pnas.012611099 <?supplied-pmid 11752410?>11752410 </plain></SENT>
</text></ref><ref id="pone.0158579.ref017"><text><SENT sid="42791" pm="."><plain>17BhaumikS, LewisXZ, GambhirSS. Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. Journal of biomedical optics. 2004;9(3):578–86. 10.1117/1.1647546 .<?supplied-pmid 15189096?>15189096 </plain></SENT>
</text></ref><ref id="pone.0158579.ref018"><text><SENT sid="42792" pm="."><plain>18DeA, LoeningAM, GambhirSS. An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer research. 2007;67(15):7175–83. 10.1158/0008-5472.CAN-06-4623 .<?supplied-pmid 17671185?>17671185 </plain></SENT>
</text></ref><ref id="pone.0158579.ref019"><text><SENT sid="42793" pm="."><plain>19MassoudTF, PaulmuruganR, GambhirSS. Molecular imaging of homodimeric protein-protein interactions in living subjects. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2004;18(10):1105–7. 10.1096/fj.03-1128fje .<?supplied-pmid 15132989?>15132989 </plain></SENT>
</text></ref><ref id="pone.0158579.ref020"><text><SENT sid="42794" pm="."><plain>20CloseDM, XuT, SaylerGS, RippS. In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors. 2011;11(1):180–206. 10.3390/s110100180 <?supplied-pmid 22346573?>22346573 </plain></SENT>
</text></ref><ref id="pone.0158579.ref021"><text><SENT sid="42795" pm="."><plain>21ZinnKR, ChaudhuriTR, SzafranAA, O'QuinnD, WeaverC, DuggerK, et al Noninvasive Bioluminescence Imaging in Small Animals. ILAR Journal. 2008;49(1):103–15. 10.1093/ilar.49.1.103 <?supplied-pmid 18172337?>18172337 </plain></SENT>
</text></ref><ref id="pone.0158579.ref022"><text><SENT sid="42796" pm="."><plain>22LeppanenO, BjornhedenT, EvaldssonM, BorenJ, WiklundO, LevinM. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006;188(2):323–30. 10.1016/j.atherosclerosis.2005.11.017 .<?supplied-pmid 16405894?>16405894 </plain></SENT>
</text></ref><ref id="pone.0158579.ref023"><text><SENT sid="42797" pm="."><plain>23LuoJ, LinAH, MasliahE, Wyss-CorayT. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(48):18326–31. 10.1073/pnas.0605077103 <?supplied-pmid 17110447?>17110447 </plain></SENT>
</text></ref><ref id="pone.0158579.ref024"><text><SENT sid="42798" pm="."><plain>24CurieT, RogersKL, ColasanteC, BruletP. Red-shifted aequorin-based bioluminescent reporters for in vivo imaging of Ca2 signaling. Molecular imaging. 2007;6(1):30–42. .<?supplied-pmid 17311763?>17311763 </plain></SENT>
</text></ref><ref id="pone.0158579.ref025"><text><SENT sid="42799" pm="."><plain>25JohnsnFH, ShimomuraO. Preparation and use of aequorin for rapid microdetermination of Ca 2+ in biological systems. Nature: New biology. 1972;237(78):287–8. </plain></SENT>
<SENT sid="42800" pm="."><plain>Epub 1972/06/28. .<?supplied-pmid 4402563?>4402563 </plain></SENT>
</text></ref><ref id="pone.0158579.ref026"><text><SENT sid="42801" pm="."><plain>26ShimomuraO, JohnsonFH, SaigaY. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. Journal of cellular and comparative physiology. 1962;59:223–39. </plain></SENT>
<SENT sid="42802" pm="."><plain>Epub 1962/06/01. .<?supplied-pmid 13911999?>13911999 </plain></SENT>
</text></ref><ref id="pone.0158579.ref027"><text><SENT sid="42803" pm="."><plain>27OrdenesVR, MorenoI, MaturanaD, NorambuenaL, TrewavasAJ, OrellanaA. In vivo analysis of the calcium signature in the plant Golgi apparatus reveals unique dynamics. Cell calcium. 2012;52(5):397–404. 10.1016/j.ceca.2012.06.008 .<?supplied-pmid 22831913?>22831913 </plain></SENT>
</text></ref><ref id="pone.0158579.ref028"><text><SENT sid="42804" pm="."><plain>28MarkovaO, LennePF. Calcium signaling in developing embryos: focus on the regulation of cell shape changes and collective movements. Seminars in cell &amp; developmental biology. 2012;23(3):298–307. 10.1016/j.semcdb.2012.03.006 .<?supplied-pmid 22414534?>22414534 </plain></SENT>
</text></ref><ref id="pone.0158579.ref029"><text><SENT sid="42805" pm="."><plain>29Teasley HamorskyK, EnsorCM, WeiY, DaunertS. A bioluminescent molecular switch for glucose. Angew Chem Int Ed Engl. 2008;47(20):3718–21. </plain></SENT>
<SENT sid="42806" pm="."><plain>Epub 2008/04/03. 10.1002/anie.200704440 .<?supplied-pmid 18383457?>18383457 </plain></SENT>
</text></ref><ref id="pone.0158579.ref030"><text><SENT sid="42807" pm="."><plain>30Teasley HamorskyK, EnsorCM, DikiciE, PasiniP, BachasL, DaunertS. Bioluminescence inhibition assay for the detection of hydroxylated polychlorinated biphenyls. Anal Chem. 2012;84(18):7648–55. </plain></SENT>
<SENT sid="42808" pm="."><plain>Epub 2012/08/23. 10.1021/ac301872u .<?supplied-pmid 22908962?>22908962 </plain></SENT>
</text></ref><ref id="pone.0158579.ref031"><text><SENT sid="42809" pm="."><plain>31ScottD, HamorskyKT, EnsorCM, AndersonKW, DaunertS. Cyclic AMP receptor protein-aequorin molecular switch for cyclic AMP. Bioconjugate chemistry. 2011;22(3):475–81. </plain></SENT>
<SENT sid="42810" pm="."><plain>Epub 2011/02/19. 10.1021/bc100486b <?supplied-pmid 21329338?>21329338 </plain></SENT>
</text></ref><ref id="pone.0158579.ref032"><text><SENT sid="42811" pm="."><plain>32HamorskyKT, EnsorCM, PasiniP, DaunertS. A protein switch sensing system for the quantification of sulfate. Analytical biochemistry. 2012;421(1):172–80. </plain></SENT>
<SENT sid="42812" pm="."><plain>Epub 2011/11/10. 10.1016/j.ab.2011.10.023 <?supplied-pmid 22067979?>22067979 </plain></SENT>
</text></ref><ref id="pone.0158579.ref033"><text><SENT sid="42813" pm="."><plain>33ZennoS, InouyeS. Bioluminescent immunoassay using a fusion protein of protein A and the photoprotein aequorin. Biochemical and biophysical research communications. 1990;171(1):169–74. </plain></SENT>
<SENT sid="42814" pm="."><plain>Epub 1990/08/31. .<?supplied-pmid 2203343?>2203343 </plain></SENT>
</text></ref><ref id="pone.0158579.ref034"><text><SENT sid="42815" pm="."><plain>34QuX, DeoSK, DikiciE, EnsorM, PoonM, DaunertS. Bioluminescence immunoassay for angiotensin II using aequorin as a label. Analytical biochemistry. 2007;371(2):154–61. </plain></SENT>
<SENT sid="42816" pm="."><plain>Epub 2007/10/13. 10.1016/j.ab.2007.08.038 .<?supplied-pmid 17931588?>17931588 </plain></SENT>
</text></ref><ref id="pone.0158579.ref035"><text><SENT sid="42817" pm="."><plain>35MirasoliM, DeoSK, LewisJC, RodaA, DaunertS. Bioluminescence immunoassay for cortisol using recombinant aequorin as a label. Analytical biochemistry. 2002;306(2):204–11. </plain></SENT>
<SENT sid="42818" pm="."><plain>Epub 2002/07/19. .<?supplied-pmid 12123657?>12123657 </plain></SENT>
</text></ref><ref id="pone.0158579.ref036"><text><SENT sid="42819" pm="."><plain>36LewisJC, DaunertS. Bioluminescence immunoassay for thyroxine employing genetically engineered mutant aequorins containing unique cysteine residues. Anal Chem. 2001;73(14):3227–33. </plain></SENT>
<SENT sid="42820" pm="."><plain>Epub 2001/07/31. .<?supplied-pmid 11476219?>11476219 </plain></SENT>
</text></ref><ref id="pone.0158579.ref037"><text><SENT sid="42821" pm="."><plain>37DesaiUA, WiningerJA, LewisJC, RamanathanS, DaunertS. Using epitope-aequorin conjugate recognition in immunoassays for complex proteins. Analytical biochemistry. 2001;294(2):132–40. </plain></SENT>
<SENT sid="42822" pm="."><plain>Epub 2001/07/11. 10.1006/abio.2001.5145 .<?supplied-pmid 11444808?>11444808 </plain></SENT>
</text></ref><ref id="pone.0158579.ref038"><text><SENT sid="42823" pm="."><plain>38DeoSK, LewisJC, DaunertS. C-terminal and n-terminal fusions of aequorin with small peptides in immunoassay development. Bioconjugate chemistry. 2001;12(3):378–84. </plain></SENT>
<SENT sid="42824" pm="."><plain>Epub 2001/05/17. .<?supplied-pmid 11353535?>11353535 </plain></SENT>
</text></ref><ref id="pone.0158579.ref039"><text><SENT sid="42825" pm="."><plain>39DeoSK, DaunertS. An immunoassay for Leu-enkephalin based on a C-terminal aequorin-peptide fusion. Anal Chem. 2001;73(8):1903–8. </plain></SENT>
<SENT sid="42826" pm="."><plain>Epub 2001/05/08. .<?supplied-pmid 11338609?>11338609 </plain></SENT>
</text></ref><ref id="pone.0158579.ref040"><text><SENT sid="42827" pm="."><plain>40RoweL, DeoS, ShofnerJ, EnsorM, DaunertS. Aequorin-based homogeneous cortisol immunoassay for analysis of saliva samples. Bioconjugate chemistry. 2007;18(6):1772–7. </plain></SENT>
<SENT sid="42828" pm="."><plain>Epub 2007/10/19. 10.1021/bc070039u .<?supplied-pmid 17941683?>17941683 </plain></SENT>
</text></ref><ref id="pone.0158579.ref041"><text><SENT sid="42829" pm="."><plain>41ShresthaS, PaengIR, DeoSK, DaunertS. Cysteine-free mutant of aequorin as a photolabel in immunoassay development. Bioconjugate chemistry. 2002;13(2):269–75. </plain></SENT>
<SENT sid="42830" pm="."><plain>Epub 2002/03/22. .<?supplied-pmid 11906264?>11906264 </plain></SENT>
</text></ref><ref id="pone.0158579.ref042"><text><SENT sid="42831" pm="."><plain>42InouyeS, NoguchiM, SakakiY, TakagiY, MiyataT, IwanagaS, et al Cloning and sequence analysis of cDNA for the luminescent protein aequorin. Proceedings of the National Academy of Sciences of the United States of America. 1985;82(10):3154–8. </plain></SENT>
<SENT sid="42832" pm="."><plain>Epub 1985/05/01. <?supplied-pmid 3858813?>3858813 </plain></SENT>
</text></ref><ref id="pone.0158579.ref043"><text><SENT sid="42833" pm="."><plain>43HeadJF, InouyeS, TeranishiK, ShimomuraO. The crystal structure of the photoprotein aequorin at 2.3 A resolution. Nature. 2000;405(6784):372–6. </plain></SENT>
<SENT sid="42834" pm="."><plain>Epub 2000/06/01. 10.1038/35012659 .<?supplied-pmid 10830969?>10830969 </plain></SENT>
</text></ref><ref id="pone.0158579.ref044"><text><SENT sid="42835" pm="."><plain>44EremeevaEV, MarkovaSV, WestphalAH, VisserAJWG, van BerkelWJH, VysotskiES. The intrinsic fluorescence of apo-obelin and apo-aequorin and use of its quenching to characterize coelenterazine binding. Febs Lett. 2009;583(12):1939–44. 10.1016/j.febslet.2009.04.043. ISI:000267797800020. <?supplied-pmid 19426732?>19426732 </plain></SENT>
</text></ref><ref id="pone.0158579.ref045"><text><SENT sid="42836" pm="."><plain>45ShimomuraO, MusickiB, KishiY. Semi-synthetic aequorin. </plain></SENT>
<SENT sid="42837" pm="."><plain>An improved tool for the measurement of calcium ion concentration. The Biochemical journal. 1988;251(2):405–10. </plain></SENT>
<SENT sid="42838" pm="."><plain>Epub 1988/04/15. <?supplied-pmid 3401214?>3401214 </plain></SENT>
</text></ref><ref id="pone.0158579.ref046"><text><SENT sid="42839" pm="."><plain>46RoweL, EnsorM, MehlR, DaunertS. Modulating the Bioluminescence Emission of Photoproteins by in Vivo Site-Directed Incorporation of Non-Natural Amino Acids. Acs Chem Biol. 2010;5(5):455–60. 10.1021/Cb9002909. ISI:000277865500004. <?supplied-pmid 20230005?>20230005 </plain></SENT>
</text></ref><ref id="pone.0158579.ref047"><text><SENT sid="42840" pm="."><plain>47GrinsteadKM. Aequorin Mutants with Site-Specifically Incorporated Non-Natural Amino Acids for Biomedical Applications. Open Access Journals: University of Miami; 2015. </plain></SENT>
</text></ref><ref id="pone.0158579.ref048"><text><SENT sid="42841" pm="."><plain>48LewisJC, Lopez-MoyaJJ, DaunertS. Bioluminescence and secondary structure properties of aequorin mutants produced for site-specific conjugation and immobilization. Bioconjugate chemistry. 2000;11(1):65–70. </plain></SENT>
<SENT sid="42842" pm="."><plain>Epub 2000/01/19. .<?supplied-pmid 10639087?>10639087 </plain></SENT>
</text></ref><ref id="pone.0158579.ref049"><text><SENT sid="42843" pm="."><plain>49TsuzukiK, TricoireL, CourjeanO, GibelinN, RossierJ, LambolezB. Thermostable mutants of the photoprotein aequorin obtained by in vitro evolution. J Biol Chem. 2005;280(40):34324–31. 10.1074/jbc.M505303200. ISI:000232229700075. <?supplied-pmid 15972815?>15972815 </plain></SENT>
</text></ref><ref id="pone.0158579.ref050"><text><SENT sid="42844" pm="."><plain>50TricoireL, TsuzukiK., CourjeanO., et al Calcium Dependence of Aequorin Bioluminescnece Dissected by Random Mutagenesis. cPNAS. 2006;103(25):5. </plain></SENT>
</text></ref><ref id="pone.0158579.ref051"><text><SENT sid="42845" pm="."><plain>51RoweL, CombsK, DeoS, EnsorC, DaunertS, QuX. Genetically modified semisynthetic bioluminescent photoprotein variants: simultaneous dual-analyte assay in a single well employing time resolution of decay kinetics. Anal Chem. 2008;80(22):8470–6. </plain></SENT>
<SENT sid="42846" pm="."><plain>Epub 2008/10/22. 10.1021/ac801209x .<?supplied-pmid 18937418?>18937418 </plain></SENT>
</text></ref><ref id="pone.0158579.ref052"><text><SENT sid="42847" pm="."><plain>52DikiciE, QuX, et al Aequorin variants with improved bioluminescence properties. Protein engineering, design &amp; selection: PEDS. 2009;22(4):243–8. </plain></SENT>
<SENT sid="42848" pm="."><plain>Epub 2009/01/27. 10.1093/protein/gzn083 <?supplied-pmid 19168563?>19168563 </plain></SENT>
</text></ref><ref id="pone.0158579.ref053"><text><SENT sid="42849" pm="."><plain>53ScottD, DikiciE, EnsorM, DaunertS. Bioluminescence and its impact on bioanalysis. Annu Rev Anal Chem (Palo Alto Calif). 2011;4:297–319. </plain></SENT>
<SENT sid="42850" pm="."><plain>Epub 2011/04/05. 10.1146/annurev-anchem-061010-113855 .<?supplied-pmid 21456969?>21456969 </plain></SENT>
</text></ref><ref id="pone.0158579.ref054"><text><SENT sid="42851" pm="."><plain>54QuX, RoweL, DikiciE, EnsorM, DaunertS. Aequorin mutants with increased thermostability. Analytical and bioanalytical chemistry. 2014;406(23):5639–43. 10.1007/s00216-014-8039-6 <?supplied-pmid 25084737?>25084737 </plain></SENT>
</text></ref><ref id="pone.0158579.ref055"><text><SENT sid="42852" pm="."><plain>55DikiciE, QuX, RoweL, MillnerL, LogueC, DeoSK, et al Aequorin variants with improved bioluminescence properties. Protein engineering, design &amp; selection: PEDS. 2009;22(4):243–8. </plain></SENT>
<SENT sid="42853" pm="."><plain>Epub 2009/01/27. 10.1093/protein/gzn083 <?supplied-pmid 19168563?>19168563 </plain></SENT>
</text></ref><ref id="pone.0158579.ref056"><text><SENT sid="42854" pm="."><plain>56LarkAR, KitamotoT, MartinJR. In Vivo Functional Brain Imaging Approach Based on Bioluminescent Calcium Indicator GFP-aequorin. J Vis Exp. 2016;(107). 10.3791/53705 .<?supplied-pmid 26779599?>26779599 </plain></SENT>
</text></ref><ref id="pone.0158579.ref057"><text><SENT sid="42855" pm="."><plain>57LewisJC, DaunertS. Photoproteins as luminescent labels in binding assays. Fresen J Anal Chem. 2000;366(6–7):760–8. </plain></SENT>
<SENT sid="42856" pm="."><plain>ISI:000086661300025. </plain></SENT>
</text></ref><ref id="pone.0158579.ref058"><text><SENT sid="42857" pm="."><plain>58RoweL, RothertA, LogueC, EnsorCM, DeoSK, DaunertS. Spectral tuning of photoproteins by partnering site-directed mutagenesis strategies with the incorporation of chromophore analogs. Protein engineering, design &amp; selection: PEDS. 2008;21(2):73–81. </plain></SENT>
<SENT sid="42858" pm="."><plain>Epub 2008/01/08. 10.1093/protein/gzm073 .<?supplied-pmid 18175778?>18175778 </plain></SENT>
</text></ref><ref id="pone.0158579.ref059"><text><SENT sid="42859" pm="."><plain>59ChatterjeeA, XiaoH, SchultzPG. Evolution of multiple, mutually orthogonal prolyl-tRNA synthetase/tRNA pairs for unnatural amino acid mutagenesis in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(37):14841–6. 10.1073/pnas.1212454109 <?supplied-pmid 22927411?>22927411 </plain></SENT>
</text></ref><ref id="pone.0158579.ref060"><text><SENT sid="42860" pm="."><plain>60ManiatisT, FritschEF, SambrookJ. Molecular cloning: a laboratory manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory; 1982 x, 545 p. p. </plain></SENT>
</text></ref><ref id="pone.0158579.ref061"><text><SENT sid="42861" pm="."><plain>61LiuCC, SchultzPG. Adding new chemistries to the genetic code. Annual review of biochemistry. 2010;79:413–44. 10.1146/annurev.biochem.052308.105824 .<?supplied-pmid 20307192?>20307192 </plain></SENT>
</text></ref><ref id="pone.0158579.ref062"><text><SENT sid="42862" pm="."><plain>62NijegorodovN, MabbsR. The influence of molecular symmetry and topological factors on the internal heavy atom effect in aromatic and heteroaromatic compounds. Spectrochimica acta Part A, Molecular and biomolecular spectroscopy. 2001;57(7):1449–62. </plain></SENT>
<SENT sid="42863" pm="."><plain>Epub 2001/07/12. .<?supplied-pmid 11446700?>11446700 </plain></SENT>
</text></ref><ref id="pone.0158579.ref063"><text><SENT sid="42864" pm="."><plain>63BakayanA, DomingoB, MiyawakiA, LlopisJ. Imaging Ca activity in mammalian cells and zebrafish with a novel red-emitting aequorin variant. Pflugers Archiv: European journal of physiology. 2014 10.1007/s00424-014-1639-3 .<?supplied-pmid 25355614?>25355614 </plain></SENT>
</text></ref><ref id="pone.0158579.ref064"><text><SENT sid="42865" pm="."><plain>64BakayanA, VaqueroCF, PicazoF, LlopisJ. Red fluorescent protein-aequorin fusions as improved bioluminescent Ca2+ reporters in single cells and mice. PloS one. 2011;6(5):e19520 Epub 2011/05/19. 10.1371/journal.pone.0019520 <?supplied-pmid 21589654?>21589654 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
